Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Cardiovascular disease (CVD), including heart disease and stroke, is the leading cause of death in the US. Every year, more than one million Americans have a heart attack, and nearly 800,000 have a stroke. In 2010, heart disease alone is expected to cost the country more than $316 billion in health care and lost productivity.
Both lifestyle changes and medication can reduce the risk of CVD, and this project combines these approaches in the hopes of identifying a practical intervention for use in primary care medical offices. The project combines two previously tested interventions and updates them to meet current guidelines for diet and use of aspirin and cholesterol-controlling drugs (statins).
The research team is delivering the combined intervention in two formats: web-based and counselor-based. Each format has the same content, but the web-based advice is accessed through the Internet by clients at home, a community site, or a primary care office. The other format involves sessions delivered to clients by a counselor either in person at a primary care office or over the telephone. The researchers will compare how effective each format is in reducing participants' risk of coronary heart disease. They will also determine the interventions' effect on participants' diet, physical activity, smoking status, medication adherence, and other health indicators. In addition, the team will compare the two formats' cost-effectiveness and how well the patients, office staff, and clinicians accept the interventions.
Recruited from five family practices, 600 patients representing the geographic and ethnic diversity of North Carolina are taking part in this study. Half the participants are randomly assigned to the web-based intervention; the other half to the counselor-based version. Both groups will also get information on local resources, such as gyms and farmers markets, that can help participants maintain a healthy lifestyle.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
North Carolina
-
Durham、North Carolina、美国、27704
- Durham Family Practice
-
Eden、North Carolina、美国、27288
- Dayspring Family Medicine
-
Kannapolis、North Carolina、美国、28081
- Cabarrus Family Medicine Residency
-
Moncure、North Carolina、美国、27559
- Moncure Community Health Center
-
Yanceyville、North Carolina、美国、27379
- Caswell Family Medical Clinic
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Established patients
- Men ages 35-79
- Women ages 45-79
- History of CVD (100 participants)
- CHD risk equal or greater than 10%
- elevated CHD risk factor
Exclusion Criteria:
- non-English speaking
- no phone
- treatment of psychosis
- history of alcohol/substance abuse within last 2 years
- pregnancy, breast feeding, or anticipated pregnancy in next 18 months
- history of malignancy, other than non-melanoma skin cancer, that has not been in remission or cured surgically for >5 years
- recent history (in past year) of hypoglycemic event requiring medical attention
- estimated creatinine clearance less than 30 ml/min
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:One-on-one counseling
Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
|
The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence).
The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
|
有源比较器:Web counseling
Participants in this arm will receive 4 intensive counseling sessions over the web.
They will also receive 3 maintenance sessions over the web.
|
The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence).
The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Predicted 10-year CHD risk
大体时间:4-month follow-up
|
Framingham risk scores are well-validated and provide an absolute estimate of the likelihood of CHD events (MI, angina, and CHD death) over a 10-year time period. We will examine absolute changes in this outcome in both intervention arms. We will also examine whether this outcome varies by subgroups of the following variables: baseline level of predicted CHD risk, age, race, SES, insurance status, overall health status, numeracy, literacy, # medications, # of perceived barriers to adherence, use of the intervention, time with the intervention, study practice site, and health counselor |
4-month follow-up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Predicted 10-year CHD risk
大体时间:12 months
|
Framingham risk scores are well-validated and provide an absolute estimate of the likelihood of CHD events (MI, angina, and CHD death) over a 10-year time period.
|
12 months
|
Use of and adherence to cardiovascular medicines
大体时间:4 and 12 months
|
Use of cardiovascular medicines will be by self-report. Adherence to cardiovascular medicines will be measured by the 8-Item Morisky scale and a single-item specifying overall percentage adherence to cardiovascular medicines(categorical). Participants will additionally report use of and adherence to individual medicines, including aspirin, blood pressure medicine, and cholesterol medicine. Aspirin adherence will be validated by serum thromboxane b2 in a subsample of participants. Blood pressure and cholesterol medicine use will be confirmed by changes in blood pressure and cholesterol. |
4 and 12 months
|
Dietary Intake
大体时间:4 and 12 months
|
Dietary intake will be measured through a combination of self-report and objective measures.
Participants will self-report diet on two validated questionnaires: the block questionnaire (fruit and vegetable intake) and the fat quality screener.
Fruit and vegetable intake will be objectively measured by serum carotenoids.
Fat quality will be objectively measured using RBC membrane fatty acids.
|
4 and 12 months
|
Physical activity
大体时间:4 and 12 months
|
Physical activity will be measured through a combination of self-report and objective measures.
Participants will report physical activity on the validated modified RESIDE questionnaire.
They will additionally wear a pedometer to monitor their daily total and aerobic steps.
|
4 and 12 months
|
Blood pressure
大体时间:4 and 12 months
|
Blood pressure will be measure via standardized protocol using an oscillometric automatic monitor
|
4 and 12 months
|
Total, HDL, and direct LDL cholesterol
大体时间:4 and 12 months
|
Total, HDL, and direct LDL cholesterol will be measured via enzymatic calorametric testing.
|
4 and 12 months
|
Smoking status
大体时间:4 and 12 months
|
Smoking will be measured through a combination of self-report and urinary cotinine (Nicalert test strips).
|
4 and 12 months
|
Adverse events
大体时间:4 and 12 months
|
We will monitor the following adverse events: ED visits (self-report), hospitalizations (self-report), deaths (family report confirmed by death registry), GI bleeds (self-report), hemorrhagic stroke (self-report), musculoskeletal injury (self-report), renal dysfunction (serum creatinine), and liver dysfunction (AST).
|
4 and 12 months
|
Acceptability of the Intervention
大体时间:4 and 12 months
|
We will measure the acceptability of the intervention using process measures querying participants, office staff, and clinicians about the perceptions of the acceptability of the intervention and the time to deliver it.
|
4 and 12 months
|
Cost-effectiveness
大体时间:4 and 12 months
|
We will measure the cost-unit CHD risk reduction for the two interventions using a societal perspective.
|
4 and 12 months
|
合作者和调查者
调查人员
- 首席研究员:Thomas C Keyserling, MD, MPH、UNC-Chapel Hill
- 研究主任:Stacey L Sheridan, MD, MPH、UNC-Chapel Hill
出版物和有用的链接
一般刊物
- Keyserling TC, Sheridan SL, Draeger LB, Finkelstein EA, Gizlice Z, Kruger E, Johnston LF, Sloane PD, Samuel-Hodge C, Evenson KR, Gross MD, Donahue KE, Pignone MP, Vu MB, Steinbacher EA, Weiner BJ, Bangdiwala SI, Ammerman AS. A comparison of live counseling with a web-based lifestyle and medication intervention to reduce coronary heart disease risk: a randomized clinical trial. JAMA Intern Med. 2014 Jul;174(7):1144-57. doi: 10.1001/jamainternmed.2014.1984.
- Sheridan SL, Draeger LB, Pignone MP, Sloane PD, Samuel-Hodge C, Finkelstein EA, Gizlice Z, Vu MB, Gitterman DP, Bangdiwala SI, Donahue KE, Evenson K, Ammerman AS, Keyserling TC. Designing and implementing a comparative effectiveness study of two strategies for delivering high quality CHD prevention: methods and participant characteristics for the Heart to Health study. Contemp Clin Trials. 2013 Nov;36(2):394-405. doi: 10.1016/j.cct.2013.07.013. Epub 2013 Aug 2. Erratum In: Contemp Clin Trials. 2014 Jul;38(2):420-3.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.